AstraZeneca Loses Bid to Block Soliris Biosimilar During Appeal

AstraZeneca Plc lost its request for an order blocking a biosimilar version of Soliris while it appeals a federal judge’s denial of a preliminary injunction in its patent-infringement lawsuit against a Samsung Biologics Co. subsidiary over the blockbuster treatment.

The emergency motion by AstraZeneca’s Alexion Pharmaceuticals Inc. unit—which followed Judge Gregory B. Williams’ rejection of its bid to block Samsung Bioepis Co.'s biosimilar of the $500,000-per-patient drug—"constitutes a motion for reconsideration” of the May 6 ruling, and Alexion “has failed to show the court clearly erred and abused its discretion,” Williams said in an order issued from the bench Monday ...